TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8121964

Group type: EXPERIMENTAL
Intervention: Vitamin E (alpha-tocopherol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo substitution after Vitamin E treatment
Number of subjects: 0
Study: 3117864

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (metered-dose inhaler, 2 mg, four times a day, or capsules, 20 mg, four times a day)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 29285796

Group type: EXPERIMENTAL
Intervention: Weight-based treatment (0.3 g/kg body weight)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual treatment (15 g for adults, 10 g for children)
Number of subjects: 37
Study: 26045533

Group type: EXPERIMENTAL
Intervention: Environmental temperature increase by 1 °C
Number of subjects: 2067

Group type: EXPERIMENTAL
Intervention: Clock genes
Number of subjects: 2067

Group type: COMPARATOR
Intervention: Environmental temperature
Number of subjects: 2067
Study: 25281992

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400mg
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Aripiprazole once-monthly 50mg
Number of subjects: 1065
Study: 23471546

Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg QD
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg QD
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg QD
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Mirabegron 200 mg QD
Number of subjects: 928

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Mirabegron (all doses)
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg and 200 mg
Number of subjects: 928
Study: 20855387

Group type: EXPERIMENTAL
Intervention: Hypothermia group (rectal temperature of 33.5°C for 72 hours)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Normothermia group (rectal temperature of 37°C)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Hypothermia group (severe HIE subgroup)
Number of subjects: 129
Study: 18774745

Group type: EXPERIMENTAL
Intervention: Endarterectomy
Number of subjects: 527

Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 527
Study: 17214385

Group type: EXPERIMENTAL
Intervention: Horizontal shaking of the vessel containing liquid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vertical lifting of the vessel containing liquid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shaking the vessel containing liquid and solid
Number of subjects: 0
Study: 12398952

Group type: EXPERIMENTAL
Intervention: High-calcium milk powder (800 mg of calcium)
Number of subjects: 100
Study: 10493473

Group type: EXPERIMENTAL
Intervention: 6-week community-based arthritis self-management program
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Baseline and 4-month changes in self-efficacy
Number of subjects: 331
Study: 8528479

Group type: EXPERIMENTAL
Intervention: Videonystagmoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy, age-matched volunteers)
Number of subjects: 0
Study: 1722834

Group type: EXPERIMENTAL
Intervention: Honvan (diethylstilbestrol diphosphate) 300 mg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Estracyt (estramustine phosphate) 560 mg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Prostal (chlormadinone acetate) 100 mg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Castration plus MTX (methotrexate) 20 mg/m2 every 2 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Castration alone
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Castration plus CPM (cyclophosphamide) 0.5-1 g/m2 every 3-4 weeks
Number of subjects: 53
Study: 7114938

Group type: EXPERIMENTAL
Intervention: Simple closure
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and drainage (VD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy with closure (PGV)
Number of subjects: 101

Group type: COMPARATOR
Intervention: VD
Number of subjects: 101

Group type: COMPARATOR
Intervention: PGV
Number of subjects: 101
Study: 30779119

Group type: EXPERIMENTAL
Intervention: Universal prevention program (n = 40 adolescents, 14 females)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-intervention control condition (n = 39 adolescents, 20 females)
Number of subjects: 79
Study: 29348711

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin ear drops plus oral placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combined oral and topical ciprofloxacin
Number of subjects: 100
Study: 27164312

Group type: EXPERIMENTAL
Intervention: Traditional memory training (Group 1)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lumosity (Group 2)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Traditional memory training and Lumosity (Group 3)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No training (Group 4)
Number of subjects: 77
Study: 24243927

Group type: EXPERIMENTAL
Intervention: Isotonic nasal saline irrigation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Isotonic nasal saline spray
Number of subjects: 127
Study: 22185494

Group type: EXPERIMENTAL
Intervention: Intracranial recordings from the fusiform gyrus
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Static and dynamic faces; happy, neutral, and fearful expressions
Number of subjects: 8
Study: 20651414

Group type: EXPERIMENTAL
Intervention: Western exercise (WE)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 132
Study: 18756344

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 200 mg per day for three days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 50
Study: 15966882

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish
Number of subjects: 16

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 16
Study: 12806591

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg + Lisinopril 20 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lisinopril 20 mg (maximum recommended dose)
Number of subjects: 80
Study: 10735266

Group type: EXPERIMENTAL
Intervention: Clinical guidelines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8840293

Group type: EXPERIMENTAL
Intervention: Treatment B (new model of hemodialysis potassium removal)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment A (standard hemodialysis)
Number of subjects: 42
Study: 1611114

Group type: EXPERIMENTAL
Intervention: 10 MU interferon-alpha 2b
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 100 MU interferon-alpha 2b
Number of subjects: 44

Group type: COMPARATOR
Intervention: 1.3 g ethoglucid
Number of subjects: 44
Study: 6560416

Group type: EXPERIMENTAL
Intervention: Technique 1 for administering subcutaneous low-dose heparin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Technique 2 for administering subcutaneous low-dose heparin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Technique 3 for administering subcutaneous low-dose heparin
Number of subjects: 43
Study: 31502862

Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1383
Study: 30851434

Group type: EXPERIMENTAL
Intervention: Prenatal and postpartum lifestyle interventions
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prenatal intervention to moderate GWG and introduce skills for weight management
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Postpartum intervention addressing weight loss
Number of subjects: 300
Study: 29221967

Group type: EXPERIMENTAL
Intervention: Computerized cognitive rehabilitation (CCR) using Erica software
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 27574838

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441 mg
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882 mg
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study: 24332668

Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt (MBTS)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Right ventricle‐to‐pulmonary artery shunt (RVPAS)
Number of subjects: 549
Study: 22984128

Group type: COMPARATOR
Intervention: Open technique (n = 33)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Endoscopic technique (n = 34)
Number of subjects: 67
Study: 19948523

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bi-level nasal CPAP
Number of subjects: 40
Study: 18497320

Group type: EXPERIMENTAL
Intervention: Continue anticoagulants for 9 additional months (RVT group)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Stop anticoagulants (RVT group)
Number of subjects: 258

Group type: COMPARATOR
Intervention: No RVT (stop OAT)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Continue OAT (RVT group)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Stop OAT (RVT group)
Number of subjects: 258
Study: 15625070

Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 92

Group type: COMPARATOR
Intervention: 4.25% dextrose
Number of subjects: 92
Study: 12574190

Group type: EXPERIMENTAL
Intervention: 60‐65 mg iodide daily for 60 days (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 60‐65 mg iodide daily for 60 days (group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 60‐65 mg iodide daily for 60 days (group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 60‐65 mg iodide daily for 60 days (all groups)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: After iodine withdrawal (all groups)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 60‐65 mg iodide daily for 60 days (group D)
Number of subjects: 40
Study: 10417466

Group type: EXPERIMENTAL
Intervention: Clonidine (3 microgram.kg‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nefopam (0.15 mg.kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline 0.9% (placebo)
Number of subjects: 60
Study: 8745846

Group type: EXPERIMENTAL
Intervention: Peak flow measurements (weekly)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: FEV1 measurements (every six months in a laboratory)
Number of subjects: 131
Study: 1906004

Group type: EXPERIMENTAL
Intervention: Ro 19-6327 (10 to 50 mg oral pre-dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: L‐deprenyl (tracer alone)
Number of subjects: 8
Study: 6728127

Group type: EXPERIMENTAL
Intervention: Fentanyl (2.5, 5.0 and 10.0 micrograms/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (1.5 and 3.0 micrograms/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 0
Study: 30138612

Group type: EXPERIMENTAL
Intervention: Reinforced education via SMS (4 days before colonoscopy)
Number of subjects: 0
Study: 29504414

Group type: EXPERIMENTAL
Intervention: School Entry Screening (SHS)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Preschool Audiology referrals
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: SHS program
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: SHS referral rates
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: SHS referral percentage
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Audiology services
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: UNHS children born after 2011
Number of subjects: 668
Study: 26297940

Group type: EXPERIMENTAL
Intervention: Hatha yoga group (n = 61)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Stretching-strengthening exercise group (n = 57)
Number of subjects: 118
Study: 24569690

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 receptor antagonist (rhIL1ra, anakinra) at a dose of 100 mg subcutaneously once a day for 5 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 receptor antagonist (rhIL1ra, anakinra)
Number of subjects: 20
Study: 22286159

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 20329654

Group type: EXPERIMENTAL
Intervention: LOS/HCTZ (losartan 50 mg/day + hydrochlorothiazide 12.5 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TEL/HCTZ (telmisartan 40 mg/day + hydrochlorothiazide 12.5 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CND/HCTZ (candesartan 8 mg/day + hydrochlorothiazide 12.5 mg/day)
Number of subjects: 42
Study: 17097378

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Number of subjects: 835

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 835
Study: 17293386

Group type: EXPERIMENTAL
Intervention: Simulated family presence
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preferred music
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo condition (horticultural text reading)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 14741060

Group type: EXPERIMENTAL
Intervention: 5 mg/d donepezil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11707842

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy (cyclophosphamide/doxorubicin/vincristine/prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factors added to CHOP chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy followed by autologous stem cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New lymphoma treatments with improved toxicity profiles
Number of subjects: 0
Study: 9394365

Group type: EXPERIMENTAL
Intervention: Dexrazoxane (Zinecard)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 150
Study: 7506168

Group type: EXPERIMENTAL
Intervention: nimesulide (300 mg/day)
Number of subjects: 660

Group type: COMPARATOR
Intervention: naproxen (750 mg/day)
Number of subjects: 660
Study: 3822278

Group type: EXPERIMENTAL
Intervention: Ritodrine plus magnesium sulfate (N = 38)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Ritodrine (N = 36)
Number of subjects: 74
Study: 31104485

Group type: EXPERIMENTAL
Intervention: BMI ≥27.5 kg/m2
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Waist circumference >100 cm (men) or >90 cm (women)
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Thresholds of BMI and waist circumference
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Maintenance of BMI and waist circumference below thresholds
Number of subjects: 3847
Study: 27620990

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Allopurinol (in participants without diabetes mellitus)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (in participants without diabetes mellitus)
Number of subjects: 80
Study: 26457580

Group type: EXPERIMENTAL
Intervention: Tesamorelin 2 mg subcutaneously daily for 6 months
Number of subjects: 806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 806
Study: 23712593

Group type: EXPERIMENTAL
Intervention: Injury from trauma exposure
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Female gender, assault, perceived life threat, and peritraumatic dissociation
Number of subjects: 236

Group type: COMPARATOR
Intervention: Model without injury
Number of subjects: 236
Study: 21054683

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 123

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 123
Study: 18838243

Group type: EXPERIMENTAL
Intervention: Intensive intervention based on self-determination theory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community care
Number of subjects: 0
Study: 17425627

Group type: EXPERIMENTAL
Intervention: Exenatide (5 or 10 microg) injected subcutaneously
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg q.d.)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Exenatide (5 or 10 microg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Exenatide (5 and 10 microg)
Number of subjects: 31
Study: 14691039

Group type: EXPERIMENTAL
Intervention: Running wheels (5.1+/‐0.8 km/d)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Moderate exercise training for 28 days
Number of subjects: 19
Study: 11744430

Group type: EXPERIMENTAL
Intervention: 3.0 g/day oral ganciclovir
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 4.5 g/day oral ganciclovir
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 6.0 g/day oral ganciclovir
Number of subjects: 281

Group type: COMPARATOR
Intervention: 5 mg/kg/day IV ganciclovir
Number of subjects: 281
Study: 9830246

Group type: EXPERIMENTAL
Intervention: Patients with hypochondriasis
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Patients with somatization syndrome
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Patients with multiple somatization symptoms
Number of subjects: 493

Group type: COMPARATOR
Intervention: Clinical control group (other mental disorders)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Nonclinical controls
Number of subjects: 493
Study: 7857998

Group type: EXPERIMENTAL
Intervention: Water exercise classes (n = 87)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Osteoarthritis participants (n = 63)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis participants (n = 24)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Rheumatoid arthritis patients (n = 48)
Number of subjects: 261
Study: 2479303

Group type: EXPERIMENTAL
Intervention: terfenadine, 240 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: terfenadine, 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 12
Study: 31290344

Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2-3 mg/day
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 1-3 mg/day
Number of subjects: 1853

Group type: COMPARATOR
Intervention: ADT + placebo
Number of subjects: 1853
Study: 28830875

Group type: EXPERIMENTAL
Intervention: Breakfast consumption (YesB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Breakfast omission (NoB)
Number of subjects: 36
Study: 26255512

Group type: EXPERIMENTAL
Intervention: Acupuncture at Zusanli (ST 36) combined with oral administration of Gexia Zhuyu decoction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Basic treatment combined with oral administration of Gexia Zhuyu decoction
Number of subjects: 120
Study: 23485014

Group type: EXPERIMENTAL
Intervention: Real high‐frequency rTMS (10 Hz, 100% resting motor threshold, 5‐sec on, 10‐sec off for 15 min; 3000 pulses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Real high‐frequency rTMS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham TMS (eSham)
Number of subjects: 16
Study: 21624752

Group type: EXPERIMENTAL
Intervention: Daily montelukast 4 mg
Number of subjects: 1771

Group type: EXPERIMENTAL
Intervention: Intermittent montelukast 4 mg
Number of subjects: 1771

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1771
Study: 19537367

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream applied to one side of the scalp and/or face for 12 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ultrabase cream (placebo) applied to the other side for 12 weeks
Number of subjects: 9
Study: 16423001

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg, amoxicillin 1 g, levofloxacin 500 mg, all given twice daily for 7 days (LAL)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily, metronidazole 400 mg thrice daily, bismuth subcitrate 120 mg and tetracycline 500 mg four times daily for 7 days (quadruple)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Lansoprazole, amoxicillin plus levofloxacin (LAL)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Quadruple therapy
Number of subjects: 106
Study: 15229013

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 600 microg 1x, 400 microg every 4 hours 5x
Number of subjects: 126

Group type: COMPARATOR
Intervention: Concentrated intravenous oxytocin plus low-dose vaginal PGE(2) 10 mg every 6 hours 4x
Number of subjects: 126
Study: 11300576

Group type: EXPERIMENTAL
Intervention: Participant anxious attachment
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Participant avoidant attachment
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Participant avoidant attachment with confederate avoidant attachment
Number of subjects: 241
Study: 9237050

Group type: EXPERIMENTAL
Intervention: Neurotoxicity Scale (patient-based report scale)
Number of subjects: 189
Study: 8431124

Group type: EXPERIMENTAL
Intervention: Two 5% povidone‐iodine enemas and 24‐hour intravenous cefotaxime sodium and metronidazole hydrochloride (Group 1)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Single injections of ceftriaxone sodium (1 g) and ornidazole (1 g) and two 5% povidone‐iodine enemas (Group 2)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Saline enemas and 24‐hour intravenous cefotaxime sodium and metronidazole hydrochloride (Group 3)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Two 5% povidone‐iodine enemas (Group 1)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Single injections of ceftriaxone sodium (1 g) and ornidazole (1 g) (Group 2)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Saline enemas (Group 3)
Number of subjects: 341
Study: 2887112

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms, four times daily for four weeks)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 225
Study: 30407682

Group type: EXPERIMENTAL
Intervention: Behavior change program and health education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 100
Study: 28035669

Group type: EXPERIMENTAL
Intervention: THRIVE pre-oxygenation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Facemask pre-oxygenation
Number of subjects: 40
Study: 25145323

Group type: EXPERIMENTAL
Intervention: Aircraft noise exposure (60 events during one night, mean sound pressure level 46.9 ± 2.0 dB(A))
Number of subjects: 60

Group type: COMPARATOR
Intervention: No noise condition (mean sound pressure level 39.2 ± 3.1 dB(A))
Number of subjects: 60